Freiraum Ventures Research
Investment Thesis
Freiraum Ventures is an early-stage venture fund based in Munich, Germany. Its stated belief is that the next generation of great companies will be built on the technologies and ideas shaping our future. Knowledge and education are the first things it looks at in a team, followed by solid business ideas and strong, committed founders. It likes entrepreneurs who have already taken first steps and shown commitment, and it wants to be the first investor in the company.
Home and Backing
The fund's home is the Strascheg Center for Entrepreneurship (SCE), the entrepreneurship center of the Munich University of Applied Sciences. The fund is backed by Prof. Dr. Falk F. Strascheg, a founding partner of EXTOREL Private Equity Advisers and one of the most experienced venture capitalists in Germany and Europe. Beyond capital, portfolio founders get knowledge, coaching and access to the SCE infrastructure and network. Founders quoted on the site describe a transparent, fast investment process and support that continued after the round, including introductions and close communication.
Stage Focus
Freiraum invests in incorporated early-stage teams and startups, at pre-seed and seed. It is a sector-agnostic investor in practice, with a visible lean toward health and medical technology, biotech, software and deep tech (quantum software, space, climate hardware). It does not back pre-incorporation ideas; the team should be a company already.
Check Size
- Ticket range: EUR 50k to EUR 200k
- Average ticket: about EUR 100k
- Average round size of its portfolio companies: about EUR 800k
- Average entry valuation: about EUR 3.5M
Lead Tendency
Freiraum writes small first cheques and most of its rounds are syndicated. In its most recent public deal, RhymeQ's $2.2M pre-seed in October 2026, Ground State Ventures led and Freiraum took part alongside Vanagon Ventures and Plug and Play. Whether it leads rounds on its own is not stated.
Recent Activity
The firm lists 18 portfolio startups. Its most recent publicly announced investment is RhymeQ, a quantum software developer-tools startup, which announced a $2.2M pre-seed round on 22 October 2026. Freiraum does not publish the stage or date of its other investments. Its portfolio page also marks a few companies as having not worked out and one as liquidated.
Portfolio Highlights
Named portfolio companies include:
- refinq
- PANTOHealth
- Voda
- Xenopatch
- INZIPIO Medical
- Get2Germany
- GetFit
- breathment
- ZEROTEC
- ONYX Biotech
- ARCSPACE
- RhymeQ
- Modelwise
- Aponia
- Oratis
- PhysioFit
Two further companies are listed as stealth.
Team
- David Photien, Partner
- Prof. Dr. Klaus Sailer, Partner
- Prof. Dr. Herbert Gillig, Partner
- Daniel Rasel, Investment Associate
- Mateo Kulis, Visiting Analyst
Decision Process
Freiraum decides as a partnership of three partners supported by an associate and an analyst. Founders apply through the application form on the website, and the fund says it actively invests. Warm introductions are not stated as required.
Founder Preferences
Founders with strong knowledge and education, often from universities and research (the partners have spoken about backing academic spin-offs), who have already incorporated and shown first traction or commitment. Founders who value hands-on help with go-to-market and growth rather than capital alone.
Geographic Focus
Munich and Germany first, with investments in companies built or expanding across Europe. Get2Germany and RhymeQ show it also backs teams with an international footprint.
How to Reach Them
Startups apply through the form on freiraum.vc or write to [email protected]. Investors can write to [email protected]. The office is at Hessstrasse 89, Munich.